Regeneron Pharmaceuticals Stock News

The stock price of ​Regeneron has seen a 6% fall over the last twenty-one trading days, while it is down 7% over the last week. The volatility in REGN stock is being driven by the developments for R

Regeneron Pharmaceuticals (REGN) and Ultragenyx Pharmaceutical (RARE) announce a license and collaboration agreement for Ultragenyx to clinically develop, commercialize and

An analyst at BofA Securities on Wednesday shared a pair trade idea in the large-cap pharma space. The Biopharma Analyst: Geoff Meacham upgraded Pfizer, Inc. (NYSE: PFE ) shares from Neutral to Buy and increased the price target from $59 to $70. The analyst downgraded Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) shares from Neutral to Sell and reduced the price target from $675 to $575. Pfizer''s Narrative to Shift To Benefits Of COVID-19 Success: The bullishness on Pfizer hinges on expectations of a dramatic rollout of Paxlovid, the company''s oral COVID-19 therapy, in 2022 and significant investments in the pipeline, Meacham said in a note. In 2022, Pfizer''s narrative will likely shift to the benefits of its COVID-19 success in the form of stepped-up pipeline/portfolio investments, the analyst said. The Paxlovid rollout should provide more durable revenues and robust cash flow, with the latter expanding the menu of strategic options around the loss of exclusivity period, he Full story available on Benzinga.

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) was a notable beneficiary of the global pandemic that resulted in a 30% increase in its stock price last year. But BofA Securities warns 2022 will be a ver

An analyst at BofA Securities on Wednesday shared a pair trade idea in the large-cap pharma space. The Biopharma Analyst: Geoff Meacham upgraded Pfizer, Inc. (NYSE:PFE) shares from Neutral to Buy and

Mad Money host Jim Cramer and the 'Squawk on the Street' team discuss shares of Regeneron and GlaxoSmithKline ahead of the market open.

Regeneron Pharmaceuticals (NASDAQ:REGN) has observed the following analyst

Shares of Regeneron Pharmaceuticals Inc. slid 1.71% to $631.52 Friday, on what proved to be an all-around poor trading session for the stock market, with the

Shares of Regeneron Pharmaceuticals Inc. advanced 1.38% to $647.28 Wednesday, on what proved to be an all-around great trading session for the stock market,

3 Biopharma Stocks Displaying Relative Strength Heading Into 2022

The latest variant of the coronavirus pandemic, Omicron, is wreaking havoc in the global stock markets. However, as some companies struggle with the adverse economic effects of the pandemic, a few cou

Diabetic retinopathy is a complication of diabetes, caused by high blood sugar levels damaging the back of the eye. It can cause blindness if left undiagnosed and untreated. However, it usually takes several years for diabetic retinopathy to reach a

Regulators say it is "unlikely" the drugs will have an effect against the new variant, pending new data.

Regeneron easily beat the revenue and EPS expectation for 3Q 2021. Rapid revenue growth will continue into the foreseeable future, thanks to strong EYLEA, Dupixent, and Covid-treatment performance.

Related Stocks: KKR , BMBL , MRK , NVDA , INTU , REGN , PYPL , UNA , UNA , FIS , SWK , AMAT , HAS , GOOGL , BAX , OKTA ,